Cite
HARVARD Citation
Drilon, A. et al. (n.d.). A phase 1/1b study of RXDX-105, an oral RET and BRAF inhibitor, in patients with advanced solid tumors. European journal of cancer. pp. S143-. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Drilon, A. et al. (n.d.). A phase 1/1b study of RXDX-105, an oral RET and BRAF inhibitor, in patients with advanced solid tumors. European journal of cancer. pp. S143-. [Online].